Duchenne Muscular Dystrophy. Muscular dystrophy
Conditions
Interventions
Intervention 1: 0.75 mg/kg/single dose/day prednisone as 50 mg tablets and in case any complications occur this dose is decreased to 0.3 mg/kg and if there still are complications, the drug is discont
Treatment - Drugs
0.75 mg/kg/single dose/day prednisone as 50 mg tablets and in case any complications occur this dose is decreased to 0.3 mg/kg and if there still are complications, the drug is discontinued and the pa
0.9 mg/kg/single dose/day deflazacort and in case any complications occur this dose is decreased to 0.5 mg/kg and if the complications are uncontrollable with this dose the patient is excluded from th
Sponsors
Pediatric Neurology Research Center of Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
No minimum to 5 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Muscular weakness below the age of 5 years; Male gender; Proximal muscle weakness; An increase of more than 40 fold the normal limit of CK in the beginning of the symptoms; Confirmation of the diagnosis by Muscle biopsy to prove dystrophin deficiency Or Genetic evaluation to confirm dystrophin gene deletion. Exclusion criteria: If the side effects of drugs deteriorate.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Muscular Weakness. Timepoint: every 3 months. Method of measurement: Designed grading. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hypertension. Timepoint: every 3 months. Method of measurement: Blood pressure monitoring. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Parvaneh Karimzadeh
Pediatric neurology Research Center
Outcome results
None listed